Healthcare / Drug Manufacturers - Specialty & GenericToronto
$8.24
+0.05 (+0.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $26.0M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$809M
P/E
137.3x
↑EV/EBITDA
13.6x
↑ROE
-0.7%
↓Gross Margin
44.5%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.3%
FCF CAGR
+22.5%
FCF margin
7.8%
FCF / Net income
-6.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $450.1M · net income $-5.4M · FCF $35.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $450.1M | $450.1M | $371.3M | $328.2M | $293.6M |
| Net Income | $-5.4M | $-5.4M | $4.3M | $-16.8M | $-29.9M |
| EBITDA | $60.3M | $60.3M | $64.4M | $40.9M | $25.3M |
| EPS | -0.05 | -0.05 | 0.04 | -0.16 | -0.26 |
| Gross Margin | 44.5% | 44.5% | 47.0% | 46.5% | 47.0% |
| Operating Margin | -0.5% | -0.5% | 2.0% | 1.9% | -5.8% |
| Net Margin | -1.2% | -1.2% | 1.2% | -5.1% | -10.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.06 | 0.09 | 0.09 |
| Current Ratio | 2.32 | 2.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $35.3M | $35.3M | $4.8M | $26.0M | $19.2M |
| Returns | |||||
| ROE | -0.7% | -0.7% | 0.5% | -2.3% | -3.6% |
| Valuation | |||||
| P/E | 137.33 | 137.33 | 134.25 | — | — |
| EV/EBITDA | 13.63 | 13.63 | 7.98 | 14.92 | 24.25 |
| P/B | 1.07 | 1.07 | 0.69 | 0.80 | 0.73 |
| Growth & Yield | |||||
| Revenue Growth | 21.2% | 21.2% | 13.1% | 11.8% | — |
| EPS Growth | -225.0% | -225.0% | 125.0% | 38.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.04 → -0.05
Residual
+43.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.